Zoek een klinische studie of trial
Andere zoekoptie(s)
98 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Terminated trial
= 
; Gefinancierd door een IRDiRC-lid = 
; Studie waarbij in minstens twee lidstaten ERN-leden betrokken zijn = 
Nationale klinische studie(s)
AUSTRALIË
Victoria
ADDRESS: NOT PROVIDED - AU
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma -AU
Institution: Information not provided - AU
BELGIË
ANTWERPEN
EDEGEM (ANTWERPEN)
SKYSCRAPER-07: Een fase III, gerandomiseerde, dubbelblinde, placebo-gecontroleerde studie van atezolizumab met of zonder tiragolumab (anti-TIGIT-antilichaam) bij patiënten met inoperabel plaveiselcelcarcinoom van de slokdarm bij wie de kanker niet is verergerd na definitieve gelijktijdige chemotherapie - BE
Antwerp University Hospital - UZA
Department of Medical Oncology
BELGIË
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - BE
Institution: Information not provided - BE
BELGIË
ARRONDISSEMENT BRUSSELS-CAPITAL
ANDERLECHT (BRUSSELS)
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - BE
Institut Jules Bordet Instituut
Service d'hématologie - Institut Jules Bordet
BELGIË
LIEGE
LIEGE
BEAT-meso: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma - BE
CHU de Liège - Domaine universitaire du Sart Tilman
Pneumologie - Allergologie
BELGIË
VLAAMS BRABANT
LEUVEN
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-CA
Institution: Information not provided - CA
DUITSLAND
Baden-Württemberg
FREIBURG
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Universitätsklinikum Freiburg
Klinik für Strahlenheilkunde
DUITSLAND
Baden-Württemberg
HEIDELBERG
NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
DUITSLAND
Baden-Württemberg
HEIDELBERG
TREASURE: Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study - DE
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
DUITSLAND
Baden-Württemberg
HEIDELBERG
CUPISCO: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy -DE
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
DUITSLAND
Baden-Württemberg
MANNHEIM
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - DE
Universitätsmedizin Mannheim
III. Medizinische Klinik
DUITSLAND
Baden-Württemberg
ULM
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -DE
Universitätsklinikum Ulm am Michelsberg
Klinik für Kinderurologie
DUITSLAND
Bayern
MÜNCHEN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
DUITSLAND
Bayern
MÜNCHEN
DEMAND: A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable HCC patients
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik II
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
AGO-OVAR 2.29: Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial - DE
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
A phase II, randomized study of MPDL3280A administered as monotherapy or in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma - DE
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without - DE
Institution: Information not provided - DE
DUITSLAND
Berlin
BERLIN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Charité - Universitätsmedizin Berlin (CBF)
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie (CBF)
DUITSLAND
Nordrhein-Westfalen
BONN
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck -DE-
Universitätsklinikum Bonn (AöR)
Medizinische Klinik und Poliklinik III - Innere Medizin (Onkologie, Hämatologie, Immunonkologie und Rheumatologie)
DUITSLAND
Nordrhein-Westfalen
DÜSSELDORF
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab -DE-
Universitätsklinikum Düsseldorf
Frauenklinik
DUITSLAND
Nordrhein-Westfalen
ESSEN
BOUQUET: A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors -DE
Evang. Kliniken Essen-Mitte gGmbH
Klinik für Gynäkologie & Gynäkologischer Onkologie
DUITSLAND
Rheinland-Pfalz
MAINZ
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma -DE
Universitätsmedizin Mainz
I. Medizinische Klinik und Poliklinik
FRANKRIJK
AUVERGNE-RHONE-ALPES
LYON
ATHENA: A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC).
CLCC Léon Bérard
Centre Léon Bérard
FRANKRIJK
BOURGOGNE-FRANCHE-COMTE
BESANÇON
TERTIO : Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study -FR
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANKRIJK
BRETAGNE
RENNES
Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma
CHU de Rennes - Hôpital Pontchaillou
CHU Rennes
FRANKRIJK
GRAND-EST
STRASBOURG
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - FR
CHU de Strasbourg - Hôpital de Hautepierre
Pôle d'Onco-hématologie
FRANKRIJK
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal - FR
Institution: Information not provided - FR
FRANKRIJK
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment -FR
Institution: Information not provided - FR
FRANKRIJK
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
TRIPLET: Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy -FR
Institution: Information not provided - FR
FRANKRIJK
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
HOLMBRAVE : Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
Institution: Information not provided - FR
FRANKRIJK
HAUTS-DE-FRANCE
LILLE
A phase Ib/II study evaluating the safety and efficacy of Atezolizumab in combination with Obinutuzumab plus Lenalidomide in patients with relapsed or refractory follicular lymphoma - FR
CHRU de Lille - Hôpital Claude Huriez
Service des Maladies du sang
FRANKRIJK
ILE-DE-FRANCE
PARIS
A Phase II, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma - FR
AP-HP. Centre - Université de Paris - HEGP Hôpital Européen Georges Pompidou
Service d'Oncologie Médicale
FRANKRIJK
OCCITANIE
MONTPELLIER
GATA : A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
CHU de Montpellier - Hôpital Saint-Eloi
Département d'Hématologie clinique
FRANKRIJK
OCCITANIE
MONTPELLIER
Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
ICM - Institut régional du Cancer de Montpellier
Service d'oncologie médicale - Médecine B3
ITALIË
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma - IT
Institution: Information not provided - IT
ITALIË
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - IT
Institution: Information not provided - IT
ITALIË
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Institution: Information not provided - IT
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma - JP
Institution: Information not provided - JP
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma
Institution: Information not provided - JP
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - JP
Institution: Information not provided - JP
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
CONTACT-03 A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment - JP
Institution: Information not provided - JP
OOSTENRIJK
OBERÖSTERREICH
LINZ
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Kepler Universitätsklinikum - Med Campus III.
Klinik für Lungenheilkunde
OOSTENRIJK
OBERÖSTERREICH
LINZ
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Ordensklinikum Linz GmbH Elisabethinen
Abteilung für Urologie und Andrologie
OOSTENRIJK
SALZBURG
SALZBURG
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Frauenheilkunde und Geburtshilfe
OOSTENRIJK
SALZBURG
SALZBURG
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
OOSTENRIJK
SALZBURG
SALZBURG
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Pneumologie/Lungenheilkunde
OOSTENRIJK
SALZBURG
SALZBURG
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Urologie und Andrologie
OOSTENRIJK
STEIERMARK
GRAZ
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
KH Barmherzige Brüder Graz - Standort Graz-Marschallgasse
Abteilung für Gynäkologie
OOSTENRIJK
TIROL
INNSBRUCK
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie und Geburtshilfe
OOSTENRIJK
TIROL
INNSBRUCK
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
AtTEnd: Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer - a randomized Phase III trial - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
TREASURE: Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
SPACE: Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
WIEN
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Krankenhaus Nord - Klinik Floridsdorf
Abteilung für Innere Medizin und Pneumologie
OOSTENRIJK
WIEN
WIEN
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - AT
Sozialmedizinisches Zentrum Baumgartner Höhe / Otto Wagner-Spital
2. Interne Lungenabteilung
OOSTENRIJK
WIEN
WIEN
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors (phase I-II) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
OOSTENRIJK
WIEN
WIEN
IMmotion010: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Onkologie
OOSTENRIJK
WIEN
WIEN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Onkologie
OOSTENRIJK
WIEN
WIEN
IMbrave050: A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
OOSTENRIJK
WIEN
WIEN
The FAB-HCC Trial: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy - AT
Universitätsklinikum - AKH Wien
Klinische Abteilung für Gastroenterologie und Hepatologie
OOSTENRIJK
WIEN
WIEN
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - AT
Universitätsklinikum - AKH Wien
Universitätsklinik für Frauenheilkunde
SPANJE
Cataluña
BARCELONA
VENEZO-LUNG: Phase Ib/II Trial of the Combination of Atezolizumab With Dendritic Cell Vaccination as Maintenance Treatment in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Induction Treatment -ES
Hospital Universitari Dexeus - Grupo Quirónsalud
Servicio de Oncología médica
SPANJE
Cataluña
ESPLUGUES DE LLOBREGAT
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors - ES (completed)
Hospital Sant Joan de Déu Barcelona
Servicio de Oncología y Hematología
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase II, randomized study of MPDL3280A administered as monotherapy or in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma - ES (completed)
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
ATALANTE: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab -ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase III, multicenter, randomized, double-blind, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - ES (completed)
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
BEAT-meso: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
CONTACT-03: A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave251: A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcinoma - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients - ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase II study exploring the safety and efficacy of atezolizumab administered in combination with obinutuzumab or rituximab amti-CD20 therapy in patients with relapsed/refractory mantle cell lymphoma, marginal zone lymphoma and Waldenström macroglobulinemia - ES (completed)
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
IMpower133: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer -ES (completed)
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
IMbrave150: A phase III, open-label, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma - ES (completed)
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A phase IIIb, single arm study of carboplatin or cisplatin plus etoposide with atezolizumab (anti-PD-L1 antibody) in patients with untreated extensive-stage small cell lung cancer - ES
Institution: Information not provided - ES
SPANJE
Madrid
MADRID
2SMALL: Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy -ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
VERENIGD KONINKRIJK
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - GB
VERENIGD KONINKRIJK
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA - GB
Institution: Information not provided - UK
VERENIGD KONINKRIJK
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase II, Randomized Study of Atezolizumab Administered as Monotherapy or In Combination With Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - GB
Institution: Information not provided - UK
VERENIGD KONINKRIJK
Hampshire
SOUTHAMPTON
ARGO A phase II study of atezolizumab with rituximab, gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large b-cell lymphoma who are not candidates for high-dose therapy GB
Southampton General Hospital
Southampton University Hospitals NHS Trust Headquarters
VERENIGD KONINKRIJK
South Glamorgan
CARDIFF
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-GB
Velindre hospital
Velindre NHS Trust
ZWITSERLAND
Suisse Alémanique
BASEL
A phase III, multicenter, randomized, Double-blind, placebo-controlled study of Atezolizumab (anti pd-l1 antibody) as Adjuvant therapy after definitive local Therapy in patients with high-risk Locally advanced squamous cell Carcinoma of the head and neck-GB
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
ZWITSERLAND
Suisse Alémanique
BERN
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - CH
Universitätsspital Inselspital
University Hospital Inselspital
ZWITSERLAND
Suisse Alémanique
LUZERN
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Luzerner Kantonsspital
Abteilung für Hämatologie
ZWITSERLAND
Suisse Alémanique
ZÜRICH
SAKK 17/18 : Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie
ZWITSERLAND
Suisse Alémanique
ZÜRICH
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Universitätsspital Zürich
Klinik für Medizinische Onkologie und Hämatologie
ZWITSERLAND
Suisse Alémanique
ZÜRICH
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - CH
Universitätsspital Zürich
Klinik für Onkologie
ZWITSERLAND
Suisse Italienne
BELLINZONA
MOLTO: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL - CH
Istituto di Ricerca in Biomedicina
Istituto oncologico di ricerca (IOR)
ZWITSERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH